A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib
- Status
- COMPLETED
- Phase
- PHASE1
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
- Status
- COMPLETED
- Phase
- PHASE2
Combination of Ibrutinib and As2O3 in the Treatment of CLL
- Status
- UNKNOWN
- Phase
- PHASE3
Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- Status
- TERMINATED
- Phase
- PHASE3
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
- Status
- COMPLETED
- Phase
- PHASE2
Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
- Status
- COMPLETED
- Phase
- PHASE2
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2